series-a
Stage
1
Investors
About
Develops a medical technology to perform lung cancer biopsy and treatment in a single hospital visit, aiming to reduce time-to-treat by combining diagnostic sampling and therapy. The company is running clinical studies (e.g., Precision Lung ISRCTN15093468) to validate its approach.
Explore Prothea Technologies's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.